Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors
July 02, 2025 06:00 ET | Source: Instil Bio US phase 1…
Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy
July 02, 2025 03:00 ET | Source: Belite Bio, Inc - 500…
Verdiva Bio to Present New Data Highlighting Once-Weekly Potential of Its Investigational Oral Obesity Candidates at the ADA 85th Scientific Sessions
Phase 1 data evaluating VRB-101, Verdiva Bio’s cAMP-biased oral GLP-1RA, provides proof…
Saudi Arabia Concludes Landmark BIO 2025 Debut as Kingdom Opens Doors to Global Biotech Collaboration
BOSTON, June 20, 2025 (GLOBE NEWSWIRE) -- Saudi Arabia has concluded its…
Parataxis Holdings LLC Announces Definitive Agreement with Bridge Biotherapeutics, Inc. (KOSDAQ: 288330), to Bring Institutionally-Backed, Bitcoin Treasury Company to the South Korean Public Markets:
SEOUL, South Korea and NEW YORK, June 20, 2025 /PRNewswire/ -- Parataxis Holdings…
TELA Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 06, 2025 16:05 ET | Source: TELA Bio, Inc. MALVERN, Pa.,…
Boundless Bio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
June 05, 2025 16:58 ET | Source: Boundless Bio, Inc. SAN DIEGO,…